NEW YORK (GenomeWeb News) — Allegro Diagnostics, which plans to commercialize molecular diagnostic products for lung cancer, has raised $4 million in a Series A financing.
 
The funding round was led by Kodiak Venture Partners and included investments by Catalyst Health Ventures and Boston University.
 
The startup company’s first commercial product will be a gene-expression based test for early-stage lung cancer.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.